The recently published results of the prospective, randomized proPSMA trial (33) confirmed that PSMA-PET/CT has higher sensitivity and specificity compared with conventional imaging (CT and bone scan) both for nodal and distant metastasis in men with high-risk prostate cancer undergoing staging before curative-intent therapy. Here, FOLH1 is linked to Familial prostate cancer.